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Inhibition of proteinase 3 by ANCA and its correlation with disease
activity in Wegener's granulomatosis. Detection of circulating anti-
neutrophil cytoplasmic antibodies (ANCA) to the neutrophil serine
proteinase, proteinase 3 (PR3), has proven valuable for the diagnosis of
Wegener's granulomatosis (WG). However, the importance of these
autoantibodies in the pathogenesis of WG remains unknown. It was
recently reported that anti-PR3 autoantibodies (PR3-ANCA) from some
patients with WG inhibit the proteolytic activity of PR3 and interfere with
the inactivation of PR3 by the physiologic inhibitor, a1-proteinase inhib-
itor (a1-PI). We have studied the effect of PR3-ANCA on the enzymatic
activity of PR3 and its correlation with disease activity in patients with
WG. We purified IgG from 21 PR3-ANCA positive sera obtained from 17
patients with WG, and determined its effect on the esterolytic and
proteolytic activity of purified human PR3 using Boc-Ala-O-Nitrophenyl
ester and fluoresceinated-elastin as enzyme substrates. Controls included
seven sera containing anti-MPO autoantibodies (MPO-ANCA) from
patients with systemic vasculitis and seven ANCA-negative sera obtained
from healthy individuals. We found that PR3-ANCA from 9 of the 17
patients significantly inhibited the activity of PR3. There was no correla-
tion between the titers of PR3-ANCA and their inhibitory activity. For one
extensively characterized autoantibody, the inhibition reached 70 to 95%
at 20-fold molar excess of IgG to enzyme, with an apparent Kapp of 56.5
/LM. This inhibition was non-competitive in nature, and was additive to
that produced by cs1-PI. A review of the clinical histories of the patients
revealed a strong association between active WG and inhibitory autoan-
tibodies. PR3-ANCA from eight of 10 patients with active disease showed
significant inhibition of PR3 activity, whereas only one of seven patients in
remission had inhibitory PR3-ANCA. These results suggest that the
inhibitory profile of PR3-ANCA maybe more reflective of disease activity
in patients with WG than the absolute titer, and suggest possible alterna-
tive mechanisms for the role of these autoantibodies in the pathogenesis
of WG.
Wegener's granulomatosis (WG) is a systemic disease of un-
known etiology which is characterized by necrotizing granulomas
in the upper and lower respiratory tract, vasculitis that can affect
multiple organ systems, and necrotizing glomerulonephritis [1, 21.
Although limited forms of the disease with no renal involvement
are commonly present early on, the disease usually becomes
generalized with time and is invariably fatal if left untreated [11.
Immunosuppressive therapy with cyclophosphamide and cortico-
steroids is generally effective in inducing remissions. The disease,
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however, has a tendency to relapse when therapy is discontinued
and long-term treatment is associated with severe side effects [3].
Precise monitoring of disease activity in WG is, therefore, of great
importance so that the immunosuppressive therapy can be tai-
lored according to the patient's need.
The recently discovered association of anti-neutrophil cytoplas-
mic antibodies (ANCA) with WG and other forms of systemic
necrotizing vasculitis, such as microscopic polyangiitis (MPA) and
renal-limited vasculitis (idiopathic necrotizing/crescentic glomer-
ulonephritis), has significantly aided the diagnosis of these disor-
ders [—71. ANCA have most commonly been detected by indirect
immunofluorescence assay using ethanol-fixed human neutrophils
as substrate. Two characteristic staining patterns have been
described: cytoplasmic or classic pattern (c-ANCA), produced by
antibodies against the myeloid lysosomal serine proteinase, pro-
teinase 3 (PR3) [8—10], and perinuclear pattern (p-ANCA),
caused by antibodies against myeloperoxidase (MPO) [6]. C-
ANCA (PR3-ANCA) have been shown to be both sensitive and
specific for active WU [5, 7, 11].
The pathogenesis of WG is poorly understood. Some available
information suggests that ANCA may be involved in the patho-
genesis of the disease. Several longitudinal studies have shown a
positive correlation between ANCA titers and disease activity,
and relapses are often preceded by a rise in ANCA titer [11—13].
Furthermore, treatment based on increase in ANCA titer has
been reported to prevent relapse [121. These findings are sup-
ported by in vitro data showing that binding of ANCA to surface
expressed PR3 (or MPO) can activate primed neutrophils, indi-
cated by the release of oxygen radicals and lysosomal enzymes [14,
15], and this can result in endothelial cell injury [16]. The in vivo
significance of this observation is unclear, however, because
neutrophil activation generally does not result in vasculitis.
Numerous studies have focused on PR3, the Wegener's autoan-
tigen, and its potential role in the pathogenesis of WG. PR3 is a
neutral serine proteinase of 29 kD with potent tissue-destructive
capacity and is found in the primary granules of neutrophils and
monocytes [17]. In addition to the proteolytic activity, PR3 has
anti-bacterial activity [18] and appears to have growth-promoting
effects on myeloid cell precursors [19]. Following activation of
neutrophils, PR3 is expressed on the cell surface and released into
the extracellular fluid (ECF) [20, 21]. A major physiologic inhib-
itor of PR3 in the ECF is a1-proteinase inhibitor (a1-PI) [22].
Recent work has shown that c-ANCA from patients with WG
interfere with PR3 proteolytic activity as well as with the binding
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of a1-PI to PR3 which was reported to correlate with disease
activity [23, 241. The authors proposed that the interference of
PR3-a1-PI binding by PR3-ANCA may prolong the half-life of
PR3 in tissues, thereby resulting in enhanced proteolytic activity
[23, 24]. However, other investigators did not find that PR3-
ANCA prevent the binding of a1-PI to PR3 [251.
We have investigated the effect of PR3-ANCA on the estero-
lytic and proteolytic activity of purified PR3, and its inhibition by
a1-PI. We have also studied the correlation of this effect of
PR3-ANCA with the clinical activity of WG. We found in several
patients with WG that PR3-ANCA significantly inhibit, in a
non-competitive manner, the esterolytic and proteolytic activity of
PR3. This inhibitory phenotype was mostly restricted to patients
with active disease, suggesting a possible role for antibody medi-
ated inhibition of PR3 in the disease process.
Methods
Serum samples
Twenty-one serum samples from 17 patients with an established
diagnosis of WG were obtained from the Clinical Immunopathol-
ogy Laboratory at the Massachusetts General Hospital. All 21
sera were positive for PR3-ANCA. The ANCA titers were
determined as part of the routine diagnostic workup of these
patients using antigen-specific radioimmunoassay (RIA) or en-
zyme-linked immunosorbent assay (ELISA) as previously de-
scribed [26, 27]. In this assay, the titers are expressed in arbitrary
units based on a standard laboratory positive serum. Values above
a cutoff of 5 units were considered positive [26]. The immuno-
globulin G (IgG) levels in these sera were either normal or slightly
elevated. None of the sera had detectable anti-MPO autoantibod-
ies (MPO-ANCA), anti-nuclear antibodies (ANA), anti-glomer-
ular basement membrane (GBM) antibodies or rheumatoid fac-
tors (RF). Control sera consisted of seven serum samples from
patients with MPO-ANCA positive vasculitis, as well as seven
serum samples obtained from healthy laboratory volunteers, that
tested negative for ANCA by ELISA. The sera were stored at
—20°C until purification of the IgG fraction was performed and
PR3 activity assayed.
Patients
The clinical findings and histologic data for each of the 17
patients were obtained from their medical records without knowl-
edge of the effect of PR3-ANCA from the patients on the catalytic
function of PR3. All 17 patients had clinical features consistent
with the diagnosis of WG [1]. In 9 of the 17 patients, the diagnosis
of WG was confirmed by histologic data that revealed necrotizing
granulomatous inflammation. In the remaining 8 patients, the
diagnosis of WG was based on clinical features and a positive test
for PR3-ANCA. Disease activity at the time the serum samples
were obtained was established according to published criteria [1,
281. Active disease was defined as progressive disease affecting
such organ systems as the upper or lower respiratory tract,
kidneys, skin, eyes or nervous system, or constitutional symptoms
that could not be attributed to processes other than WG. Remis-
sion was defined as complete absence of evidence for active
disease, with a stabilized or improved renal function with no
further evidence of active sediment (although proteinuria may
persist for months or years in the presence of completely inactive
renal disease) and complete resolution of pulmonary infiltrates, or
evidence of stable scarring without signs of active inflammation.
Isolation of serum IgG
The sera were fractionated by 50% ammonium sulfate. The
precipitates were redissolved in 10 m sodium phosphate/150 mM
sodium chloride, pH 7.4 (PBS) and dialyzed against the same
buffer with two exchanges [29]. The IgG fractions were further
affinity-purified on protein-G agarose columns. Bound IgG was
then acid-eluted and the eluate immediately neutralized. Anti-
body concentrations were determined spectrophotometrically at
A280 [29]. The homogeneity of the purified IgG fractions was
confirmed in each case by SDS-PAGE (8.25%) as described by
Laemmli [30], followed by Coomassie staining. Under reducing
conditions, only two bands of 50 kD and 25 kD were seen,
representing the heavy and light chains of IgG respectively (data
not shown).
Enzymatic reactions
Reactions using N-t-Boc-L-Alanine p-Nitrophenyl ester (Boc-
Ala-ONp) as substrate [22, 31] were initiated by adding the
desired amount of the substrate to a 3 ml cuvette that contained
0.51 ig of enzyme in reaction buffer. The reactions were moni-
tored in a Pharmacia-LKB spectrophotometer at 347 nm and
25°C. OD readings were taken at 1, 3, 5, 7, 10 and 15 minutes and
adjusted for the spontaneous hydrolysis of Boc-Ala-ONp by
simultaneously running a control sample containing only buffer
and substrate. After establishing the baseline activity of PR3,
esterolysis was assayed in the presence of antibody or a1-PI. The
enzyme was preincubated with the antibody or a1-PI, in one ml of
the same reaction buffer at 25°C for 30 minutes, then buffer was
added to a final volume of 3 ml. All experiments were done at
least in duplicate.
Proteolysis of elastin was assayed by adding 1.9 tg of PR3, or
1.0 g of human neutrophil elastase (Sigma Chemicals, St. Louis,
MO, USA) to 300 ml of reaction buffer containing 0.5 mg
FITC-elastin, and the reaction monitored as previously described
[18].
Reagents
Human neutrophil PR3 was purified by affinity chromatography
using monoclonal antibody 1E8 coupled to sepharose as we
previously described [9]. Purity was assessed by SDS polyacryl-
amide gel electrophoresis and by N-terminal sequencing. N-t-Boc-
L-Alanine p-Nitrophenyl ester was purchased from Bachem Inc.
(Torrance, CA, USA) in powder form and dissolved in dimethyl
formamide (DMF) to a 300 m stock solution. FITC-elastin
200—400 mesh was purchased from ICN Biochemicals (Cleveland,
OH, USA) and suspended in 50 m sodium phosphate buffer, pH
5.5, to a final concentration of 1.67 mg/ml. Protein G was
purchased from Pharmacia-LKB (Piscataway, NJ, USA) as Hi-
Trap protein G-sepharose minicolumns, and from BRL-GIBCO
(Bethesda, MD) as protein G-agarose suspension. Alpha-i-pro-
teinase inhibitor (a1-PI) was purchased from Calbiochem (La
Jolla, CA, USA), and dissolved to 10 mg/mI stock solution in 50
m sodium phosphate buffer, pH 7.5, with 0.05% Triton X-100
(reaction buffer).
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Computational methods
Initial reaction velocities were obtained from slopes determined
by linear regression of OD readings, A347 versus time graphs using
CricketGraph software. OD readings were all adjusted for back-
ground representing the spontaneous hydrolysis of Boc-Ala-ONp
absorption at A347. Actual velocities were determined based on
the extinction coefficient 5.5 X iO M1 cm1 [221. PR3
activity in the presence of antibody or c1-PI was calculated as
(Vexp/Vb=e) X 100where Vexp is the experimental velocity, that is,
a reaction containing IgG or a1-PI, and Vbase is the velocity of a
reaction containing only PR3. Kinetic constants were determined
using Lineweaver-Burk, Woolf-Augustinsson-Hofstee, and Dixon
plots [32—361. Descriptive statistics yielding values for the mean
and standard error, and Student's t-test analyses were calculated
with the use of StatWorks computer software. Reaction slopes of
all samples containing PR3-ANCA and MPO-ANCA were ana-
lyzed against the mean slope of 14 reactions containing enzyme
and IgG from seven normal subjects and inhibition was consid-
ered significant when P < 0.05 on the Student's I-test.
Results
Fig. 1. Lineweaver-Burke plot of PR3 activity using Boc-Ala-ONp as sub-
strate over a concentration range of 0.1—0.5 m. Reaction velocities were
calculated by linear regression as explained under Methods.
Steady state kinetics of PR3
It was previously shown that PR3 effectively hydrolyzes the
p-nitrophenyl ester of alanine [22]. We therefore used Boc-Ala-
ONp as a substrate to study the esterolytic activity of the enzyme.
Under the conditions described above, the hydrolysis reaction
reached its steady-state plateau in 15 minutes at 25°C, and the
optimal substrate concentration range was between 0.1 and 0.5
m. Moreover, the rate of hydrolysis increased linearly with
increased substrate concentration, indicating that it had no allo-
steric effect on the activity of the enzyme. In addition, because of
a previous report [37] showing a stimulating effect of increasing
hydrophobicity on elastase function, the effect of the solvent,
DMF, was studied and was found to have no effect on the
enzyme's activity over a concentration range of 10 to 30% (data
not shown). The Kapp for the substrate Boc-Ala-ONp was found
to be 0.656 mM as determined from a Lineweaver-Burk plot (Fig.
1). This value is in agreement with that derived by Rao et al [22].
Effect of PR3-ANCA #1 and a1-PI on PR3 esterolytic activity
The initial studies analyzing the effects of PR3-ANCA on PR3
activity were performed using purified IgG from serum #1
(subsequently referred to as PR3-ANCA #1), because large
amounts of this serum were available. This antibody was preincu-
bated with PR3 in varying molar ratios followed by measurements
of the esterolytic activity of PR3. At a constant Boc-Ala-ONp
substrate concentration of 0.20 m, a clear inhibitory pattern of
the enzyme was observed in a dose-dependent pattern (Fig. 2A).
Maximal PR3 inhibition was observed at an enzyme to lgG molar
ratio of 1:20 and ranged between 70 and 95% in various enzyme
preparations. At 1:20 ratio, a control serum IgG containing
MPO-ANCA was non-inhibitory (Fig. 2A). This ratio was there-
fore subsequently used for all other antibodies tested. A Dixon
plot analysis performed at variable substrate and PR3-ANCA #1
concentrations showed an apparent non-competitive pattern of
inhibition of this antibody with a Kapp of 56.5 iM (Fig. 2B).
To compare these values with those obtained by the physiologic
inhibitor u1-PI, this inhibitor was incubated with PR3 under
similar conditions and its inhibitory profile analyzed. As shown in
Figure 3A, a1-PI also produced a dose-dependent inhibition of
PR3 catalytic activity. This inhibition was independent of the
substrate concentration used (0.1—0.5 m range, not shown),
reached a plateau at an a1-PI:PR3 molar ratio of —15:1 and was
further enhanced by 70% upon addition of PR3-ANCA #1.
Inhibition by a1-PI was competitive in nature (Fig. 3B) as
previously shown [22] with a mean apparent K1app of 0.40 I.LM.
The differences in K1app between the PR3-ANCA and cs1-PI may
be more apparent than real since total IgG rather than only
anti-PR3 antibody was used in this analysis. These data also
suggest that both inhibitors, the PR3-ANCA and the a1-PI, inhibit
PR3 function by binding to different regions of the enzyme.
PR3-ANCA from other WG patients also inhibit PR3 activity
in vitro
The effect of purified IgG from 20 additional PR3-ANCA
positive sera, obtained from 16 patients with WG, on PR3 activity,
was studied next. IgG was preincubated with PR3 at an enzyme to
IgG molar ratio of 1:20. Controls consisted of IgG from seven
MPO-ANCA positive patients with systemic vasculitis, and IgG
from seven healthy subjects that tested negative for ANCA. The
results are shown in Figure 4A. IgG from the normal subjects had
no effect on PR3 activity. The mean of 14 reactions containing
PR3 and IgG from the seven normal individuals is displayed in
Figure 4A. PR3-ANCA from five of the sixteen patients (PR3-
ANCA #2—6), inhibited PR3 esterolytic activity almost com-
pletely (mean 70 to 95% inhibition, P < 0.05), similar to that
observed with PR3-ANCA #1. In follow-up samples available on
two of these patients, #2F and #5F, the inhibitory activity had
decreased to statistically insignificant levels. In three additional
patients (#7—9), the degree of inhibition was less severe (41 to
58%), although statistically significant (P < 0.05). The follow-up
serum (#7F) from patient #7, obtained only one day after the
initial sample, showed persistent inhibition. In the remaining eight
patients, PR3 inhibition was variable but did not reach statistical
significance (P> 0.05). Among the seven MPO-ANCA positive
sera, only one (MPO-ANCA #7, Fig. 4A), showed moderate,
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Fig. 2. Inhibition of the esterolytic activity of PR3 by PR3-ANCA #1. (A)
Dose-response curve showing the inhibitory activity of PR3-ANCA #1
(LI). No such activity was seen in purified serum IgG from a patient with
circulating MPO-ANCA (•) at a PR3-IgG molar ratio of 1:20. Values
represent the mean 5EM of two independent experiments, each carried
out in duplicate. A regression analysis of these points confirms the validity
of the antibody's inhibitory effect as reflected by the negative slope (r =
0.986; y = 97.317 — 3.2496x). (B) Dixon plot analysis of PR3 activity with
increasing PR3-ANCA #1 concentration from 6.9 to 134 M based on the
same PR3-IgG molar ratio calculations that were used in panel A.
Boc-Ala-ONp concentration range is again from 0.1 to 0.5 mivi. Note that
the intersection site of the reaction lines (arrow) suggests a noncompeti-
tive pattern of inhibition according to Dixon [35, 36]. This experiment is
one of three independent experiments and shows an apparent Ki (K1app)
of 56.5 j.M (range 50 to 63 tM).
Ki=O.40 ISM
Fig. 3. Inhibition of PR3 by a1-PI. (A) Lineweaver-Burk analysis of PR3
activity showing the inhibition of PR3 by a1-PI. The enzyme was pre-
incubated with the inhibitor for 30 minutes at 25°C in 1 ml of reaction
buffer. Subsequently 2 ml of reaction buffer were added and the reaction
was initiated by addition of substrate and monitored as described in
Methods. Inhibition reached a plateau at 14 jsg of a1-PI per reaction and
was further increased by addition of PR3-ANCA #1(1:20 enzyme:IgG
molar ratio). (B) Dixon plot analysis of the PR3 esterolytic activity with
increasing cs1PI concentration from 1.4 to 10 jsM, and a substrate
concentration of 0.1 to 0.5 mi. In three independent experiments, one of
which is shown here, the Kapp ranged from 0.35 to 0.45 M. Here, the
reaction line intersection (arrow) suggests a competitive inhibition pattern
[35, 36].
PR3-ANCA inhibit the elastinolytic activity of PR3
Our analysis of the effects of the anti-PR3 autoantibodies on
the esterolytic function of PR3 was extended to the proteolysis of
elastin, a known protein substrate for PR3 which may account for
its potent capacity of inducing emphysema in hamster lungs in vivo
[17]. Figure 5 shows a dose-response curve of the inhibitory effect
of PR3-ANCA #1 on PR3 activity determined by a fluorometric
assay using FITC-elastin as substrate. In contrast, no inhibition of
PR3-ANCA #1 on human neutrophil elastase activity was ob-
served (data not shown), further indicating that the activity
observed was directed specifically against PR3 and that the
purified IgG fraction was not contaminated by natural serum
proteinase inhibitors such as cs1-PI or a2-macroglobulin. The
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albeit significant (P < 0.05) degree of PR3 inhibition. No corre-
lation was found between the PR3-ANCA titers (quantified using
antigen-specific ELISA) and their inhibitory activity (r = 0.05 1;
Fig. 4B).
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Fig. 5. Inhibition of the elastinolytic activity of PR3 by PR3-ANCA #1 (E).
No inhibition was observed using an MPO-ANCA positive IgG (•). A
dose-response curve shows the inhibition of PR3-initiated proteolysis of
the fluoresceinated FITC-elastin by that autoantibody. Values represent
the mean SEM of two independent experiments.
Fig. 4. Effect of PR3-ANCA and MPO-ANCA
on the esterolytic activity of PR3. (A) Each
histogram represents PR3 activity in the
presence of purified IgO from PR3-ANCA
positive patients with WG (indicated by
numbers below each bar) and MPO-ANCA
positive controls. Also displayed is the mean
PR3 activity obtained from 14 reactions
containing enzyme and IgG from 7 normal
subjects (C). Histograms represent the mean
SEM of two independent experiments. An
asterisk (*) indicates that the sample's activity
is significantly (P < 0.05) different from that
seen with IgG from normal subjects. None of
the MPO-ANCA positive sera is positive for
PR3-ANCA as determined by ELISA. (B) Lack
of correlation between PR3-ANCA titers and
inhibitory profile. A linear regression analysis of
PR3-ANCA titer vs. PR3 inhibition shows no
correlation (r = 0.051; y = 43.012 — 1.2269e-
2x).
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MPO-ANCA and one negative for ANCA, had any inhibitory
effects (data not shown).
Clinical characteristics and disease activity in the patient
population
After determining the effects of PR3-ANCA on the activity of
PR3, the clinical and histologic findings were reviewed and the
disease activity at the time of serum collection was determined.
The clinical manifestations, the date of the most recent episode of
active disease (initial diagnosis or relapse), the presence or
absence of therapy (cyclophosphamide with or without corticoste-
roids) and its duration, PR3-ANCA titer and PR3 activity in the
presence of PR3-ANCA are shown in Table 1. The inhibitory
effect of PR3-ANCA is displayed as a mean value of at least two
determinations and expressed as % of "normal" PR3 activity
(mean PR3 activity when tested in the presence of IgG from 7
normal individuals). Table 1 shows that PR3-ANCA with PR3
inhibitory activity represent mainly patients with active disease.
Eight of the 10 patients with active disease showed statistically
significant inhibition of PR3, whereas two patients did not. One of
the two patients (#10) had a long (13 year) history of WG and was
thought to have smoldering disease, that is, a stable form of mild,
active disease. The other patient (#14) had made significant
recovery after six weeks of immunosuppressive therapy although
he had not yet reached complete remission, In two patients, #2
and #5, follow-up samples (#2F and #5F) revealed that the
PR3-ANCA inhibitory pattern paralleled closely its effect on the
esterolytic activity of PR3. Moreover, all seven of the inhibitory
PR3-ANCA tested also inhibited the elastinolytic activity of the
enzyme, and none of three control IgG samples, two containing
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Table 1. Demographics
Disease duration PR3
at time of PR3- activity
Serum ANCA Disease Date of Dx or last ANCA Organ involvement at Therapy ANCA % of# Sex date state relapse (Re) determination Dx or Re duration titer Ni
1 F 8/2/90 Active 7/17/90 (Dx) 2 weeks L, K (Dx) + (2 wks) 7 7.5
2 F 5/5/89 Active 5/6/89 (Dx) 0 days ENT, L, K, M, J (Dx) — 128 20.3a
2F 6/7/89 Active — 1 month — + (1 month) 31 85.8a
3 M 12/26/91 Active 1/2/92 (Dx) 0 days ENT, L, K, J, PNS (Dx) — 64 15.P
4 F 5/26/89 Active 5/5/89 (Re) 16 months ENT, L, K (Dx) + (3 wks) 29 15.4a
5 M 9/20/91 Active 9/20/91 (Dx) 0 days
Fever, anemia
ENT, K, EY, 5, J
(Re)(Dx) — 83 15.4
SF 10/14/91 Active — 24 days — + (10 days) 76 67.6a
6 M 3/18/91 Remission 12/88 (Dx) 27 months L, K (Dx) — 17 19.6
7 M 7/22/91 Active 7/22/91 (Dx) 0 days ENT, K, EY (Dx) — 512 41.1
7F 7/26/9 1 Active — 4 days — + (1 day) 563 67.4a
8 M 4/25/90 Active 12/7/89 (Dx) 4.5 months ENT, EY
EY
(Dx) +
(Re)
(4.5 mos) 28 52.2a
9 M 1/31/91 Active 10/90 (Re) 22 months ENT, L, EY, S, J
Ey
(Dx) +
(Re)
(3 mos) 642 577
10 M 11/13/91 Active 1/91 (Re) 13 years ENT, L, K
ENT, L
(Dx) +
(Re)
(22 mos) 56 70.3
11 F 8/15/90 Remission 11/88 (Dx) 21 months ENT, L, K, EY (Dx) + (21 mos) 20 77.3
12 M 1/17/91 Remission 11/78 (Dx) 13 years ENT, L, K (Dx) — 988 86.4
13 M 6/27/91 Remission 3/5/90 (Dx) 15 months ENT, L (Dx) + (15 mos) 25 63.0
13F 10/31/91 Remission — 19 months — + (19 mos) 57 90.8
14 M 3/12/91 Active 2/1/91 (Dx) 6 weeks ENT, L (Dx) + (6 wks) 38 113.1
15 F 10/15/9 1 Remission 3/88 (Re) 4.5 years ENT, L (Dx) — 62 86.0
16 M 1/24/91 Remission 12/89 (Dx) 13 months L, EY, 5, J (Dx) + (13 mos) 2688 88.9
17 F 9/25/91 Remission 3/89 (Re) 11 years ENT (Dx) — 398 63.2
Summary of clinical characteristics of PR3-ANCA positive patients whose sera were studied. ANCA date refers to the date that ANCA determination
was performed. Dx refers to diagnosis and Re to relapse. Disease duration refers to the time that elapsed from initial diagnosis until the time of ANCA
determination. Organ involvement includes: ENT, ear, nose and throat; L, lung; K, kidney; Ey, eye; S, skin; M, muscle; J, joints; and PNS, peripheral
nervous system.
inhibitory activity had decreased to nonsignificant levels after
immunosuppressive therapy of 1 month and 10 days duration,
respectively. Patient #2 did also receive plasma exchange therapy,
which may have accounted for the fourfold decrease in PR3-
ANCA titer observed in the follow-up sample, suggesting that
depletion of PR3-ANCA may have contributed to the rapid
decline in inhibition. In the follow-up sample from patient #5,
however, the inhibitory activity was reduced in the absence of a
significant change in PR3-ANCA titer. The follow-up sample
(#7F) from patient #7 was taken only one day after initiating
immunosuppressive therapy. One patient, who was in complete
remission, showed statistically significant inhibition of PR3. Data
on the subsequent course of that patient are lacking so we do not
know whether the patient suffered a clinical relapse during the
ensuing months. All the six remaining patients were in remission
at the time of ANCA testing and none had statistically significant
inhibition.
Discussion
The detection of ANCA directed against PR3 has proven
valuable for the diagnosis of WG [5, 7, 1 1]. The strong association
between PR3-ANCA and WG suggests that the presence of
ANCA is not merely an epiphenomenon but rather has a role in
the pathogenesis of the disease.
The data presented in this paper show a strong correlation
between inhibition of PR3 caused by PR3-ANCA and disease
activity in patients with WG (Table 1). In contrast, we found little
correlation between PR3-ANCA titer and disease activity. Al-
though several studies have shown a strong correlation between
ANCA titers and disease activity in WG, it is well known that
clinical recovery is not always accompanied by a decrease in
ANCA titer and persistently high titers are observed in some
patients with inactive disease, as is demonstrated by patients #12,
16, and 17 in our study. Moreover, a recent report by Kerr et al
showed that changes in ANCA titers correlated with changes in
disease status in only 64% of patients and that increase in ANCA
titer preceded relapse in only 24% [281. Our data suggest that
PR3-ANCA-mediated inhibition of PR3 may be a better marker
for active WG than the PR3-ANCA titer. A prospective study
involving a larger group of patients will be needed to confirm this
finding.
In one extensively characterized PR3-ANCA, the inhibition of
PR3 appeared to be non-competitive in nature and additive to
that observed with the natural inhibitor a1-PI, suggesting that the
inhibitors act at different sites on the enzyme. This finding differs
from other investigators [23] who reported that in addition to
inhibiting PR3 activity, PR3-ANCA from patients with WG also
interferes with the binding of a1-PI to PR3, measured by RIA.
Subsequent work by the same group [24] showed that the latter
phenomenon correlated with disease activity, leading the authors
to postulate that this interference may enhance the proteolytic
activity of PR3 by increasing its half-life in the ECF. In that study
however, the median inhibition of PR3-a1-PI complex formation
in patients with active WG was only 22%. The authors did not
report functional data showing the effect of this interference on
PR3 activity. They also found in plasma samples from their
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patients that the level of PR3-a1-PI and HLE-a1-PI complexes
were within the range of those in normal healthy controls, Gross,
Schmitt and Csernok could not confirm that PR3-ANCA inter-
feres with the binding of a1-PI to PR3 [25]. Except for PR3-
ANCA #1, we did not have enough serum available to to analyze
in detail the effect of the remaining PR3-ANCA on the binding of
a1-PI to PR3.
Our data indicate that the inhibition of PR3 is the result of a
highly specific interaction between certain PR3-ANCA and PR3.
First, no inhibition was observed when PR3 activity was assayed in
the presence of seven ANCA-negative and six out of seven
MPO-ANCA IgG. The only exception was one MPO-ANCA,
which showed moderate PR3 inhibition. It is possible that this
serum did in fact contain PR3-ANCA that escaped detection in
the ELISA because of a lower avidity for the antigen. Reactivity to
both PR3 and MPO in patients with systemic vasculitis has been
reported in rare cases [38]. Secondly, several PR3-ANCA, some
with very high titers (all significantly higher than the titer of
PR3-ANCA #1), had no inhibitory effects on PR3, again suggest-
ing that the inhibition is not due to a non-specific effect of
antibody-antigen complex formation, but rather to the interaction
of certain autoantibodies with one or more functional epitopes on
PR3. Finally, none of the inhibitory PR3-ANCA inhibited HLE
despite its high homology with PR3 (54% sequence identity) [39].
Our data also show that the inhibitory phenotype of the
autoantibody may change rapidly during the course of the disease,
perhaps in response to therapy. We are not aware of any reports
of such a phenomenon in other human autoimmune diseases. In
experimental models of autoimmune diseases, such as experimen-
tal allergic encephalomyelitis and insulin-dependent diabetes
mellitus, an "evolution" of the T cell receptor repertoire to an
autoantigen has been demonstrated [40, 41]. In these experimen-
tal animals, T cell clones react initially with a confined region of
the autoantigen and, in a relatively short period of time (days),
expand to involve additional determinants. An analogous immune
"maturation" response has been described for autoantibodies
against the ribonucleoprotein La(SSB) in patients with Sjögren's
syndrome [42]. We speculate that a similar phenomenon may
occur in response to immunosuppressive therapy, changing the
autoantibody profile from an inhibitory to a non-inhibitory one as
was observed in patient #5 (Table 1). Epitope heterogeneity
among PR3-ANCA has recently been shown, using overlapping
7-amino acid peptides based on the sequence of PR3 [43]. This
analysis also showed that certain autoantibodies recognize part of
the catalytic triad and the surrounding region. This suggests that
steric as well as allosteric mechanisms may underlie the inhibitory
phenotype of various PR3-ANCA.
It has previously been reported for several autoimmune dis-
eases that autoantigens that are enzymes are inhibited by their
respective autoantibodies. Anti-mitochondrial antibodies in pa-
tients with primary biliary cirrhosis are directed against the
pyruvate dehydrogenase complex and inhibit its enzymatic func-
tion [44, 45]. Autoantibodies to RNA-polymerase I, found in
small number of patients with scieroderma, inhibit the synthesis of
28S and 18S RNA [46]. Autoantibodies to tRNA synthetases from
patients with polymyositis inhibit tRNA aminoacylation [47, 48].
The significance of the autoantibody mediated inhibition in these
disorders is unclear, since these enzyme targets are solely ex-
pressed intracellularly and, therefore, are not accessible to the
autoantibodies. This may explain why none of these autoantibod-
ies have been found to be pathogenic or shown to be strongly
associated with disease activity. In contrast, an inhibitory autoan-
tibody directed against the plasma serine proteinase thrombin was
recently reported in a young man with a symptomatic bleeding
disorder who suffered a fatal cerebral hemorrhage, indicating a
direct pathogenic role of the anti-thrombin antibody [49].
The inhibition of PR3 activity by certain PR3-ANCA may be an
epiphenomenon of no physiologic significance. It is well estab-
lished that autoantibodies in human autoimmune diseases react
predominantly with highly conserved epitopes, which often rep-
resent functional or catalytic domains of the target antigens [50].
As discussed above, in several diseases autoantibodies have been
found to inhibit the function of their enzyme autoantigens without
a clear relationship to the disease process. Since the catalytic site
of a serine proteinase is highly conserved [51], it is not surprising
that this region may be the target of autoantibodies. It is possible
that the close correlation between active disease and inhibitory
autoantibodies observed here could be a manifestation of the
primary autoimmune response, and may suggest that the disease
process is of a relatively short duration with the autoantibody
repertoire still directed against the conserved immunodominant
epitope of the autoantigen, similar to what has been described for
the T cell receptor repertoire in early experimental EAE and
IDDM [40, 41]. In fact, six of eight patients with active disease and
inhibition of PR3 in our study were in the early stages of their
disease.
Alternatively, an inhibitory autoantibody may play a pathophys-
iologic role by interfering with an essential down-regulatory
function of PR3 in the inflammatory response that may be
particularly relevant in certain tissues such as the lung. It is
intriguing that in the respiratory tract where the early lesions in
WG frequently occur, epithelial secretions are relatively lacking in
specific PR3 inhibitors [22]; the circulating a1-PI has relatively low
avidity for PR3, and the bronchial secretory leukoprotease inhib-
itor, a potent inhibitor of elastase, does not inhibit PR3 [22].
ANCA have been detected in bronchoalveolar lavage fluid from
patients with WG and there is evidence that ANCA are produced
in the respiratory tract of these patients [52]. Testing the validity
of this hypothesis will require an elucidation of the physiologic
substrates of PR3 in vivo. Inhibition of PR3 by autoantibodies as
a potential mechanism of injury in WG does not exclude other
mechanisms of tissue injury, such as autoantibody-induced neu-
trophil activation [14, 15], and T cell-mediated cytotoxicity [53].
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